Skip to main content

Jenna Strickland

Jenna StricklandCooperating Doctoral Program: Pharmacology & Toxicology

EITS Track: Biomedical Toxicology

Education: B.S. Biochemistry, North Carolina State University

Research Interests: There are several known causes of cholestatic liver disease, including autoimmune destruction of bile duct epithelial cells, genetic disorders, and physical obstruction of the bile duct. Chronic and persistent hepatic inflammation leads to liver injury and fibrosis, making it a critical factor in the progression of cholestatic liver disease.  However, current anti-inflammatory therapies remain unsuccessful for most patients, rendering available treatment options therapeutically ineffective in reducing hepatic inflammation.  This ultimately places many patients with cholestatic liver disease at increased risk for liver failure.  Therefore, a more targeted anti-inflammatory therapeutic approach, aimed specifically at reducing hepatic inflammation is needed to reduce liver injury and fibrosis during cholestasis.  While the mechanism through which cholestasis induces hepatic inflammation remains unknown, identification of the key pathways involved in this process will provide insight into potential drug targets aimed exclusively at reducing hepatic inflammation.  My research involves identifying these pathways and determining the mechanism by which cholestasis stimulates hepatic inflammation.

Major Professor: Bryan Copple, Pharmacology & Toxicology

Contact: stric100@msu.edu